PHARMA MAR, S.A. «12345...» Page 5 out of 20 26/04/2023 18:05 PHARMA MAR, S.A. On corporate governance The Company informs about the resignation of a director and changes in the composition of the Board of Directors and its Committees. Register number: 22124 26/04/2023 17:57 PHARMA MAR, S.A. Other relevant information - On business and financial situation The Company files first quarter 2023 financial information and announces a conference call with analysts and investors. Register number: 22122 17/04/2023 11:14 PHARMA MAR, S.A. Other relevant information The Executive Committee of Pharma Mar, S.A. has decided to implement the Free of Charge Stock Ownership Plan approved by resolution of the General Shareholders’ Meeting of 29 June 2022. Register number: 21950 11/04/2023 08:26 PHARMA MAR, S.A. On credit ratings Axesor maintains long-term credit rating of Pharma Mar. Register number: 21823 10/04/2023 16:48 PHARMA MAR, S.A. Liquidity and counterparty agreements The Company reports details of the operations of the Liquidity Agreement between 01/01/2023 and 31/03/2023 Register number: 21817 08/03/2023 11:09 PHARMA MAR, S.A. On business and financial situation The Company announces the approval of Zepzelca® (lurbinectedin) for the treatment of metastatic Small Cell Lung Cancer in Switzerland Register number: 21210 28/02/2023 17:13 PHARMA MAR, S.A. Annual report on directors´ remunerations La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del Ejercicio 2022 Register number: 20971 28/02/2023 17:12 PHARMA MAR, S.A. Annual corporate governance report La sociedad remite el Informe Anual de Gobierno Corporativo del ejercicio 2022 Register number: 20970 28/02/2023 16:10 PHARMA MAR, S.A. Annual financial reports and audit reports La sociedad remite el Informe Financiero Anual del ejercicio 2022 Register number: 20956 28/02/2023 15:38 PHARMA MAR, S.A. Other relevant information - On business and financial situation The Company reports draw up of the Annual Financial Statements 2022, a proposal for a dividend, and a conference call with analysts and investors. Register number: 20955 Page 5 out of 20 «12345...»